Flu A+B

BD Veritor™ Plus System

Influenza A + B rapid antigen testing

Be ready for flu outbreaks

Seasonal flu outbreaks are routinely caused by the two main types of influenza, A and B, and account for 3-5 million cases of severe illnesses per year and up to 650,000 deaths worldwide¹. 

During the flu season, certain people, including children under five, pregnant women and the elderly are at risk of being hospitalized for flu-related complications¹.

Accurate detection and diagnosis of flu and beginning a regimen of influenza antiviral drugs within the first 48 hours of symptom onset, are important for the most effective treatment².

BD Veritor™ Plus System
for Flu A + B

The BD Veritor™ System for Rapid Detection of Flu A+B is a rapid chromatographic immunoassay. 

The system provides rapid, reliable results, and offers one-button functionality for workflow flexibility, allowing health care providers to confidently use the Analyzer.

Nasal sample icon

Simple sample collection with nasal and nasopharyngeal swabs3-4

Clock icon

Fast, reliable results in as few as 11 minutes3-4

BD Veritor Plus Analyzer icon

Dual testing capability distinguishes Flu A from Flu B

Computer screen icon

Two analysis options to optimize workflow

The BD Veritor™ System for Rapid Detection of Flu A+B assay products meet the FDA Class II special controls applicable to RIDTs for analytical reactivity testing.

Rapid flu test clinical performance data

We know that a test is only as good as the reliability of its results. We compared the performance of the BD Veritor™ System for Rapid Detection of Flu A+B test to an FDA-cleared Influenza A and B molecular assay (PCR) ³.

Comparison of BD Veritor™ System for Rapid Detection of Flu A+B Test to PCR

 

Data shows a high comparative positive percent agreement, and a high negative percent agreement — both of which indicate the reliability of the BD Veritor™ Plus System.

BD Flu A Clinical Kit

83.0%

Positive Percent Agreement

(95% C.I 78.0-87.0%)
97.6%

Negative Percent Agreement

(95% C.I 96.6-98.3%)

BD Flu A Clinical Kit3,4
REFERENCE PCR

BD Veritor TM

  P N Total
P 224 29 253
N 46 1,172 1,218
Total 270 1,201 1,471

Reference method : PCR

Sensitiivity : 83.0% (95% CI: 78.0-87.0%)

Specificity : 97.6% (95% CI: 96.6-98.3%)

BD Flu B Clinical Kit

81.3%

Positive Percent Agreement

(95% C.I 72.1-88.0%)
99.8%

Negative Percent Agreement

(95% C.I 99.4-99.9%)

BD Flu B Clinical Kit3,4
REFERENCE PCR

BD Veritor TM

  P N Total
P 74 3 77
N 17 1,377 1,394
Total 91 1,380 1,471

Reference method : PCR

Sensitiivity : 81.3% (95% CI: 72.1-88.0%)

Specificity : 99.8% (95% CI: 99.4-99.9%)

Explanation of Terms:  

Positive percent agreement (PPA) indicates the proportion of individuals who tested flu positive with PCR that also test positive with the antigen test

Negative percent agreement (NPA) indicates the proportion of individuals who tested flu negative with PCR that also tested flu negative with the antigen test

P: Positive
N: Negative
C.I.: Confidence Interval

BD Veritor™ Plus System ordering and reimbursement

As your facility continues to provide valuable rapid diagnostic testing, you may need to reorder. Please click here for more information.

Quick Reference Instructions

See how the BD Veritor™ Plus System can help support you and your organization.

Instructions for Use

Learn more about the BD Veritor™ System for Rapid Detection of Flu A+B

REFERENCES

  1. www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). Accessed December 19, 2018
  2. https://www.cdc.gov/antivirals/whatyoushould.html
  3. BD Veritor System for Rapid Detection of Flu A+B, CLIA-waived kit [package insert], 8087667. Franklin Lakes, NJ: Becton, Dickinson and Company.
  4. BD Veritor System for Rapid Detection of Flu A+B, laboratory kit [package insert], 8087666. Franklin Lakes, NJ: Becton, Dickinson and Company.